Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-Current Assets (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Non-Current Assets for 6 consecutive years, with $25.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 7.8% to $25.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $106.4 million, a 8.5% decrease, with the full-year FY2025 number at $25.7 million, down 7.8% from a year prior.
  • Non-Current Assets was $25.7 million for Q4 2025 at Janux Therapeutics, down from $26.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $32.2 million in Q2 2023 to a low of $215000.0 in Q2 2021.
  • A 5-year average of $23.6 million and a median of $27.8 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 12597.67% in 2022, then fell 10.64% in 2024.
  • Janux Therapeutics' Non-Current Assets stood at $2.8 million in 2021, then surged by 1025.53% to $31.6 million in 2022, then dropped by 1.28% to $31.2 million in 2023, then fell by 10.64% to $27.8 million in 2024, then dropped by 7.8% to $25.7 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Non-Current Assets are $25.7 million (Q4 2025), $26.7 million (Q3 2025), and $26.7 million (Q2 2025).